Thank you for your comments and questions, and your welcome for the delivery of this part of the programme for government. I’m happy to reconfirm the point about the appraisal process for other new forms of technology. The new treatment fund we’re talking about is for the delivery of new and approved medicines. In terms of your point about horizon scanning for new medicines; that is part of what we’ve got better at in Wales because we’ve had a change in the nature of our relationship with the industry. That maturity really matters to us, to make sure that our public service values are secure, and that the value we get for the new medicines for the health service and for patients is maintained as our first priority—but equally, understand how we maximise the opportunities for that to be the case, and to make sure that, if there are other benefits that can be taken in terms of the ability to develop the industrial potential for this industry in Wales, we take those up too.

But, actually, we recognise, with the industry having a different relationship, that it’s actually in their interest to have this grown-up conversation with us. If they want their new medicines to be made available, to be properly appraised so they can understand what they will do in a patient access scheme if that is required, to understand all of the advice and information that is required to allow the appraisal to be undertaken rapidly and effectively and then delivered, it is in their interest to have that conversation about what is coming on stream in the future. I’m genuinely optimistic about that—not from the simple point of being a naturally optimistic person, but actually the conversations that we’ve had with industry. I particularly welcome and recognise the supportive comments made today by the Association of the British Pharmaceutical Industry on the introduction of the fund.

The point about new medicines—and again, on the point that this isn’t just about choosing cancer as our only basket of conditions where we’re prepared to spend additional money in this way—in the launch for the new treatment fund I actually went to the blood-borne viruses clinic in the Heath. It’s an all-Wales service and it does a quite amazing job for people right across the country. What’s really changed there is not just the access to new medication that we’ve delivered with new money—that’s made a huge difference for the staff and the way they network and work across Wales—it’s actually delivered a real sense of clinical purpose in the way they talk about the way they want to deliver this on a genuine all-Wales basis. So, the new money and the new medicines have actually been part of helping to change real progress in clinical behaviour, treatment and outcomes for patients. Because that, for me, was the most inspiring part of the visit—to meet patients who have actually now had a genuine cure as a result of the new medication that’s been introduced on the back of the specific investment that’s been made. That’s what I want to see more of now and in the future. So, good news for the health service, but even better news for the patients that the health service serves.